Abstracts tagged "interstitial lung disease"

Abstract Number: 0939 • ACR Convergence 2023
HRCT-derived Delta Radiomic Features Classify Response to Anti-Fibrotic Treatment in Experimental and Human Fibrosing Interstitial Lung Disease
David Lauer¹, Luca Romano Kolly¹, Hubert Gabrys², Matthias Brunner¹, Malgorzata Anna Maciukiewicz¹, Thomas Frauenfelder³, Stephanie Tanadini-Lang², Anne-Christine Uldry⁴, Manfred Heller⁴, Kerstin Klein⁵, Oliver Distler⁶, Janine Gote-Schniering¹ and Britta Maurer⁷, ¹University Hospital Bern, Bern, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University of Bern, Bern, Switzerland, ⁵Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷University Hospital Bern, University Bern, Bern, Switzerland
Background/Purpose: Quantification of response to anti-fibrotic drugs in patients with fibrosing interstitial lung disease (ILD) relies on repeated pulmonary function tests (PFT) and visual evaluation…
Abstract Number: 1269 • ACR Convergence 2023
The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes
Gregory McDermott¹, Keigo Hayashi¹, Pierre-Antoine Juge², Ritu Gill¹, Suzanne Byrne¹, Staci Gagne¹, Kathleen Vanni¹, Emily Kowalski¹, Grace Qian¹, Katarina Bade³, Alene Saavedra¹, Yumeko Kawano¹, Michael Diiorio³, Taylor Wolfgang¹, Edy Kim¹, Paul Dellaripa³, Michael Weinblatt⁴, Nancy Shadick³, Tracy J. Doyle¹ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD…
Abstract Number: 1724 • ACR Convergence 2023
Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Attenuates Experimental Pulmonary Fibrosis Through Mitochondria Transfer Mediated Anti-apoptotic and Immunomodulatory Effects
Hanna Lee¹, Suhee Kim², Mingyo Kim², Ok-Yi Jeong³ and Sang-Il Lee², ¹Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, South Korea, ²Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Hospital, JinJu, South Korea, ³Division of Rheumatology, Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, South Korea
Background/Purpose: Interstitial lung disease (ILD) is a serious condition characterized by inflammation and fibrosis in the lung interstitium. The important subtypes of ILD include idiopathic…
Abstract Number: 2158 • ACR Convergence 2023
Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Mueller⁶, Steven Sambevski⁷ and Wim A Wuyts⁸, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁸Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital capacity (FVC) compared with placebo,…
Abstract Number: 2595 • ACR Convergence 2023
A Randomized Controlled Trial to Compare the Efficacy and Safety of Tacrolimus with Mycophenolate Mofetil in Patients with Systemic Sclerosis – Interstitial Lung Disease ( INSIST TRIAL)
Shefali Khanna Sharma¹, Jithin Mathew¹, Chirag Kopp¹, Varun Dhir², Sahajal Dhooria³, Anindita Sinha¹ and Sanjay Jain¹, ¹Post Graduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³PGI CHANDIGARH, Chandigarh, India
Background/Purpose: Interstitial lung disease in systemic sclerosis(SSc-ILD) is heterogeneous with limited therapeutic options. Mycophenolate mofetil (MMF) is the most commonly used first line agent for…
Abstract Number: 0296 • ACR Convergence 2023
Does Presence of Anti-SSa and Ro52 Influence the Progression of Interstitial Lung Disease (ILD) in Idiopathic Inflammatory Myopathies (IIM)
Sonali Narain¹, Can Hu², Michael Liu¹, Kourosh Shargani³ and Galina Marder¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Fort Lee, NJ, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
Background/Purpose: Anti-SSa and Ro52 are commonly present in IIM. We previously reported an association of a more severe early course of IIM-ILD with positive Ro52.…
Abstract Number: 0645 • ACR Convergence 2023
Continuous Progressive ILD in Systemic Sclerosis Is Associated with Mortality
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Oyvind Midtvedt¹, Carina Mihai⁶, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: We have previously shown that short term progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) is associated with mortality. However, it is…
Abstract Number: 0949 • ACR Convergence 2023
Development of Interstitial Pneumonia with Autoimmune Features in Conditional Tgfb3 Deletion
Toshihiko Komai¹, Tomohisa Okamura², Masanori Kono¹, Kazuhiko Yamamoto³ and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: We found that TGF-β3 regulates humoral immunity in a context-dependent manner [1]. Recent genome-wide association study reveals that TGF-β3 might be a novel target…
Abstract Number: 1296 • ACR Convergence 2023
Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study
Bradly Kimbrough¹, Cynthia Crowson¹, John Davis¹, Eric Matteson² and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN
Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with…
Abstract Number: 1733 • ACR Convergence 2023
Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease
Nozima Aripova¹, Michael Duryee¹, Amy Nelson¹, Carlos Hunter¹, Breanna Butler¹, Bryant England¹, Jill Poole¹, Geoffrey Thiele¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a leading cause of mortality in RA with limited treatment options as well as lack of available…
Abstract Number: 2165 • ACR Convergence 2023
Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Natividad del Val del Amo³, Ivette Casafont-Sole⁴, Rafael Benito Melero-Gonzalez⁵, Isabel Serrano-García⁶, Santos Castañeda⁷, Jerusalem Calvo⁸, Natalia Mena Vazquez⁹, Nuria Vegas Revenga¹⁰, Lucía Domínguez-Casas¹¹, Maria Camila Osorio Sanjuan¹², Carolina Díez Morrondo¹³, Lorena Perez-Albadalejo¹⁴, Ruben Lopez-Sanchez¹⁵, Maria Guadalupe Mazano Canabal¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez-Viejo¹⁸, Gema Bonilla¹⁹, Olga Maiz-Alonso²⁰, Carmen carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno²³, Ana Urruticoechea²⁴, Sergio Ordonez-Palau²⁵, Carmen Gonzalez-Montagut Gomez²⁶, andrea Garcia-Valle²⁷, Juan Ramon De Dios²⁸, Fernando Lozano²⁹, Tomás Vazquez-Rodriguez³⁰, Patricia Carreira²⁹, Juan Maria Blanco-Madrigal³¹, SARA MARIA ROJAS HERRERA³², Ignacio Brana Abascal³³, Jesus Loarce-Martos³⁴, Emilio Giner-Serret³⁵, Juan Camilo Sarmiento-Monroy³⁶, Clara ventin-Rodriguez³⁷, Marina Rodriguez-lopez³⁸, Pablo Andujar-Brazal³⁹, Julia Fernandez-Melon⁴⁰, Lilian Maria Lopez⁴¹, carlos Fernandez-Diaz⁴², Javier Loricera⁴³, Ivan Ferraz Amaro⁴⁴, Diego Ferrer⁴⁵, Ricardo Blanco⁴⁶ and On behalf of the Collaborative Group Members⁴⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ³Complejo Hospitalario de Navarra, Pamplona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶Division of Rheumatology, H. Puerta del Mar, Cádiz, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Reina Sofia University Hospital, Córdoba, Spain, ⁹IBIMA, Málaga, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Division of Rheumatology, Hospital San Agustín, Avilés, Spain, ¹²Division of Rheumatology, H.U. Lozano Blesa, Zaragoza, Spain, ¹³Division of Rheumatology, Hospital de León, León, Spain, ¹⁴Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Complejo Asistencial de Zamora, Zamora, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ¹⁹Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁰University Hospital Donostia, San Sebastian, Spain, ²¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ²²H. de Sagunto, Valencia, Italy, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Can Misses, Ibiza, Spain, ²⁵H. Arnau de Vilanova, Lleida, Spain, ²⁶H. Clínico Universitario de Valladolid, Valladolid, Spain, ²⁷Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁸Hospital Universitario Araba, Vitoria, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁰Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ³¹Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ³²Division of Rheumatology, Hospital de Mérida, Mérida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Ramón y Cajal University Hospital, Madrid, Spain, ³⁵Hospital Royo Villanova, Teruel, Spain, ³⁶Hospital Clínic, Barcelona, Spain, ³⁷Division of Rheumatology, Hospital Universitario de A Coruña, A Coruña, Spain, ³⁸Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ³⁹Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴⁰Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴¹Division of Rheumatology, Hospital Universitario Son Llàtzer, Mallorca, Spain, ⁴²Division of Rheumatology, Hospital Universitario Reina Sofía, Murcia, Spain, ⁴³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁴⁵Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁷Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis, Spain, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Usual interstitial pneumonia (UIP) is the most frequent, and severe ILD…
Abstract Number: 2596 • ACR Convergence 2023
Head-To-Head Comparison of the Effectiveness of Tocilizumab, Rituximab, Mycophenolate Mofetil, and Cyclophosphamide in Patients with SSc-ILD from the EUSTAR Database
Qingran Yan¹, Cosimo Bruni², Alexandru Garaiman², Carina Mihai², Suzana Jordan², Mike Becker³, Muriel Elhai⁴, Rucsandra Dobrota², liubov Petelytska³, Anna-Maria Hoffmann-Vold⁵, Joerg Henes⁶, Eric Hachulla⁷, Elise Siegert⁸, Alexandra Balbir-Gurman⁹, Giovanna Cuomo¹⁰, Gabriela Riemekasten¹¹, Stefan Heitmann¹², valeria Riccieri¹³, Susanne Ullman¹⁴, Petros Sfikakis¹⁵, Francesca Ingegnoli¹⁶, Vera Bernardino¹⁷, Marie-Elise Truchetet¹⁸, Francesco Del Galdo¹⁹, SHUANG YE²⁰ and Oliver Distler², ¹Department of Rheumatology, University Hospital Zurich, Zurich, Swaziland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴University Hospital zurich, University of Zurich, Zurich, Switzerland, ⁵Oslo University Hospital, Oslo, Norway, ⁶University Hospital Tuebingen, Tuebingen, Germany, ⁷University of Lille, Lille, France, ⁸Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ¹¹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹²Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, ¹³Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, ¹⁴Department of Dermatology, University Hospital of Copenhagen, Hospital Bispebjerg, Copenhagen, Denmark, ¹⁵National Kapodistrian University of Athens Medical School, Athens, Greece, ¹⁶Universita' degli Studi di Milano, Milano, Italy, ¹⁷Centro Hospitalar Lisboa Central, Lisbon, Portugal, ¹⁸Bordeaux University Hospital, Bordeaux, France, ¹⁹University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ²⁰Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: Tocilizumab (TCZ), rituximab (RTX), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) are the immunosuppressants (IS) with the current best evidence for the treatment of systemic…
Abstract Number: 0297 • ACR Convergence 2023
Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population: Case Series
Eaman Alhassan¹, Belina Yi², Jack Rodman¹ and Leanna Wise³, ¹University of Southern California, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA, ³LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: There is little to no data about the presentation and clinical course of anti-melanoma differentiation-associated gene-5 antibody (anti-MDA-5) dermatomyositis patients in a primarily U.S.…
Abstract Number: 0651 • ACR Convergence 2023
Abnormal Nailfold Video-capillaroscopy Is Independently Associated with non-UIP Radiographic Patterns in Autoimmune ILD: A Multicenter Study from the NEREA Registry
Jesus Loarce-Martos¹, Hilda Godoy², Laura Cebrian³, M Jesus Rodriguez-Nieto⁴, Juan Rigual⁵, Rosalía Laporta², Belen Lopez-Muñiz³, lydia Abasolo⁶, Olga Sanchez Pernaute⁷ and Fredeswinda Romero⁷, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Hospital Universitario Infanta Leonor, Madrid, Spain, ⁴Pulmonology department, Hospital Fundación Jimenez Díaz, Madrid, Spain, ⁵Pulmonology department, Hospital Ramón y Cajal,, Madrid, Spain, ⁶Hospital Clínico San Carlos, Madrid, Spain, ⁷IIS-HU Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: The aim of this study is to describe the nailfold video-capillaroscopy (NVC) findings in patients with interstitial lung disease associated to connective tissue diseases…
Abstract Number: 0950 • ACR Convergence 2023
KL-6 and IL-18 Levels Are Negatively Correlated with Respiratory Function Tests and ILD Extent Assessed on HRCT in Patients with Systemic Sclerosis-related Interstitial Lung Disease (SSc-ILD)
Cristiana Sieiro Santos¹, Sara Calleja², Javier de la Calle Lorenzo², Carmen López Garay², Clara Moriano², Elena Bollo de miguel² and Elvira Díez Álvarez², ¹Complejo Asistencial Universitario de León, León, Spain, ²CAULE, León, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Serum biomarkers have been suggested as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.